Navigation Links
Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
Date:7/30/2008

is about shielding the neuronal cells in the brain from degeneration or death. Therefore, ANAVEX's potent neuroprotective compound may offer disease-modifying treatment and not merely symptomatic relief from Alzheimer's disease. Moreover, the compound does not target pathologoanatomic hallmarks, such as amyloid-plaques, whose role has turned out to be controversial, since approaches to inhibit them have failed to provide compelling benefit.

Anavex's approach is based on the exploitation of the multiple modulation properties of Sigma-1 receptors, which are as of yet unexploited by the existing drugs in the market. Sigma-1 receptors are proteins that regulate the activity of other different proteins (like IP3 receptors or ER stress sensors) and also of sodium and calcium channels. Moreover, through their modulatory role, Sigma-1 receptors are able to regulate cellular apoptotic processes.

Unlike the challenge of pro-amyloid and anti-amyloid theories of AD, Anavex Life Sciences' SIGMACEPTOR(TM) Discovery Platform sigma-1 activator molecules target neuronal intracellular structures with the goal of preventing neurodegenerative action of disturbed biochemical pathways and channels.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (http://www.anavex.com) is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases such as Alzheimer's, epilepsy and depression. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.

ANAVEX's SIGMACEPTOR(TM)-N program involves the developme
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
2. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
3. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
6. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
9. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... 31, 2014 Adventist Health System, ... U.S. including Florida Hospital Tampa, Florida Hospital Carrollwood, ... Hospital North Pinellas, Florida Hospital Wesley Chapel, Florida ... Florida Hospital Heartland Medical Center Lake Placid and ... list of Most Wired Hospitals and Health Systems, ...
(Date:7/31/2014)... Peninsula, MI (PRWEB) July 31, 2014 The ... preparation of the upcoming harvest. And, to celebrate, folks are ... Saturday and Sunday, September 6 and 7, 2014 along the ... festivities is an optional walk or run through the vineyards ... Winery in Suttons Bay. A unique course between rows of ...
(Date:7/31/2014)... July 31, 2014 Weblify has finally been ... years of development and testing. The result is a ... in as little as 5 minutes without knowing any HTML ... review , Shane Michaels, an SEO expert, agrees that this ... “I’ve seen a lot of web site builders out there, ...
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... of its faculty, Anthony Le Donne and Peter J. ... Also new to United is a Director of ... August 1. , Anthony Le Donne, Assistant Professor ... United Kingdom. He teaches New Testament, Second Temple Judaism, ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Growing Seminary Welcomes New Faculty 2
... alternative remedies more likely to misuse prescribed drugs, suffer ... Many asthma patients who use herbal remedies experience increased ... shows. , Researchers followed 326 asthma patients for 33 ... herbal remedies and used prescribed inhaled corticosteroids (ICS) less ...
... Insurance Companies Amend Policy on Radioembolization Coverage , OTTAWA, ... global leader in providing products and services for medical ... largest health insurers in the United States ... liver cancer, which includes the use of MDS Nordion,s ...
... , ... costs, boost efficiency , SILVER SPRING, Md. , ... Administration today issued guidance on Bayesian statistical methods in the ... result in less costly and more efficient patient studies. , ...
... recognized as a complication of erosive esophagitis and is ... A research team from Yokohama City University School of ... might be useful for identifying a subgroup with a ... study will be published on January 28, 2010 in ...
... Whitewater Courses and ... challenge participants with hard-to-hear truths about the responsibilities of developers who promote atop the ... designers, engineers and river scientist will take place May 24-27, 2010 in Salida, CO. ... (PRWEB) March 3, 2010 -- ...
... sugar of children, teens stable longer , THURSDAY, Feb. 4 ... teenagers with type 1 diabetes could benefit by using an ... blood sugar levels during sleep and help them control their ... issue of The Lancet , examined use of an ...
Cached Medicine News:Health News:Herbals Not the Answer for Asthma, Study Shows 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 3Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 4Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 2Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 3Health News:Hard Green Truths - Keynotes Suggest New Value Propositions for River Park Leaders 2Health News:Artificial Pancreas Helps Type 1 Diabetics During Sleep 2
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: